^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
SAR441000
i
Other names: SAR441000, SAR 441000, BNT131
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
BioNTech, Sanofi
Drug class:
IL-15R agonist, IFNα stimulant, IL-12 stimulant, Cytokine modulator, GM-CSF stimulant
Related drugs:
8ms
A phase 1, first-in-human, dose-escalation, expansion trial of cytokine encoding synthetic mRNA-mixture alone or with cemiplimab in advanced solid tumors. (PubMed, Clin Cancer Res)
Intratumoral administration of SAR441000 in combination with cemiplimab, was generally well tolerated with anti-tumor activity in loco-regional disease setting. Anecdotal evidence of pharmacodynamic immune-modulatory effect and distant non-injected lesion anti-tumor response was observed, without significant effect in patients with advanced solid tumors previously treated with anti-PD1 therapies.
P1 data • Journal
|
IFNG (Interferon, gamma) • IFNA1 (Interferon Alpha 1) • IL15 (Interleukin 15)
|
Libtayo (cemiplimab-rwlc) • SAR441000
almost2years
A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=77, Terminated, Sanofi | Completed --> Terminated; Sponsor terminated the study for non-safety reasons
Trial termination • Combination therapy • Metastases
|
Libtayo (cemiplimab-rwlc) • SAR441000
almost2years
A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=77, Completed, Sanofi | Active, not recruiting --> Completed
Trial completion • Combination therapy • Metastases
|
Libtayo (cemiplimab-rwlc) • SAR441000
5years
[VIRTUAL] A first-in-human study of intratumoral SAR441000, an mRNA mixture encoding IL-12sc, interferon alpha2b, GM-CSF and IL-15sushi as monotherapy and in combination with cemiplimab in advanced solid tumors (SITC 2020)
These data support further clinical evaluation of SAR441000. Ethics Approval The study was approved by each participating Institution’s Ethics or Institutional Review Board(s).
P1 data • Combination therapy
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CSF2 (Colony stimulating factor 2) • GZMB (Granzyme B)
|
Libtayo (cemiplimab-rwlc) • SAR441000
5years
[VIRTUAL] A first-in-human study of intratumoral SAR441000, an mRNA mixture encoding IL-12sc, interferon alpha2b, GM-CSF and IL-15sushi as monotherapy and in combination with cemiplimab in advanced solid tumors (SITC 2020)
These data support further clinical evaluation of SAR441000. Ethics Approval The study was approved by each participating Institution’s Ethics or Institutional Review Board(s).
P1 data • Combination therapy
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CSF2 (Colony stimulating factor 2) • GZMB (Granzyme B)
|
Libtayo (cemiplimab-rwlc) • SAR441000
Share via
